Paul Foster

Pulse Biosciences (United States) — United States

Arts and Humanities · Social Sciences

27h-index2.6kcitations604works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Biblical Studies and Interpretation(260), Historical and Linguistic Studies(144), Archaeology and Historical Studies(48), Historical, Religious, and Philosophical Studies(46), Christian Theology and Mission(36)

Publications603 total

Small Books in Early Christianity KrugerMichael J., Miniature Codices in Early Christianity, OECS (Oxford: OUP, 2025. £84.00. pp. vii + 218. ISBN: 978-0-19-894039-5).
The Expository Times·2025
Abstract A023: Erythropoietin (EPO) is a Pharmacodynamic Biomarker for Systemic HIF-2α Inhibition that Correlates with the Clinical Activity of Casdatifan
Molecular Cancer Therapeutics·2025
Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
British Journal of Clinical Pharmacology·2025· 1 citedOpen Access
47A Comparison of Metzger’s Category {D} Readings With the Textual Decisions of the <i>Editio Critica Maior</i>
2025
Fourth-Century Monks of Nag Hammadi TuttyPaula, The Monks of the Nag Hammadi Codices: Contextualising a Fourth-Century Monastic Community, NHMS 107 (Leiden: Brill, 2024. €130.00. pp. xii + 328. ISBN: 978-90-04-69574-0).
The Expository Times·2025
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
Journal of Clinical Oncology·2025· 1 cited
PLK1 and multi-CDKs dual inhibition as a novel approach for the treatment of adrenocortical carcinomas
Endocrine Abstracts·2025
Commentary on the Wisdom of Sirach WilsonWalter T., The Wisdom of Sirach, ECC (Grand Rapids, Michigan: Eerdmans, 2023. $85.99/£69.99. pp. xvi + 620. ISBN: 978-0-8028-8176-2).
The Expository Times·2025Open Access
Empowering students in endocrine science: the establishment of the MSS summer school
Endocrine Abstracts·2025
Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
2025
Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.
Journal of Clinical Oncology·2025· 3 cited
Book Review: Early Commentary Tradition on James
The Expository Times·2025
Abstract A012: Discovery and characterization of Casdatifan (AB521), a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor
Molecular Cancer Therapeutics·2024· 2 cited
Book Review: Essays on Jesus as Teacher
The Expository Times·2024
4 Oral: Casdatifan in patients (pts) with previously treated clear cell renal cell cancer (ccRCC) and other solid tumors; preliminary results from ARC- 20: A phase 1, open-label dose-escalation and expansion study
European Journal of Cancer·2024· 1 cited
Ancient Letters and the New Testament
The Expository Times·2024· 6 cited
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer
The Oncologist·2024· 1 citedOpen Access
Figure S5 from Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells
2024Open Access
Figure S10 from Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells
2024Open Access
Data from Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells
2024Open Access
page 1 of 31Next →

Frequent Co-authors

Scott Gettinger(6), Rebecca S. Heist(6), Johanna C. Bendell(5), Koho Iizuka(4), Laura Q.M. Chow(4), Jayesh Desai(4), Genevive Hernandez(4), Edward Cha(4), Peter Lamb(4), Afshin Dowlati(4), Indrani Sarkar(4), Carol O’Hear(4), Roel Funke(3), John D. Powderly(3), Jeffrey J. Wallin(3), Peiwen Yu(3), Toshihiro Yamaguchi(3), Christopher T. Jaeger(3), Chris A. Buhr(3), Arthur Plonowski(3)